₹24.14
▼ -0.3 -1.23%
29 Jul 2026
NSE Listed · Pharmaceuticals
Balaxi Pharmaceuticals Ltd. (BALAXI)
Volume: 11,774Avg Vol 1W: 14,909Avg Vol 1M: 22,05952W Range:₹15.2₹52.5
Key Ratios
Checked just nowMarket Cap₹133 Cr
Current Price₹24.14
Previous Close₹24.44
High / Low (52w)₹52.5 / ₹15.2
Volume11,774
Avg Vol (1W)14,909
Avg Vol (1M)22,059
Stock P/E219.45
Book Value₹45.12
Dividend Yield0%
ROE0.57%
ROA0.42%
Revenue (TTM)—
Revenue Growth21.25%
Profit Margin0.53%
Total Debt₹21 Cr
Shares Outstanding6 Cr
Face Value₹2
EPS (TTM)₹0.11
P/B0.54
Debt / Equity0.23
50 DMA₹24.16
200 DMA₹27.38
Day change-1.23%
Price Chart
₹24.14▼ 49.55% · 1Y
2025-07-292026-07-29
20-day avg volume: 21K shares
Pros
- Company is almost debt-free.
- Stock trades below its book value.
Cons
- Revenue fell 18% YoY.
- Stock trades at a high P/E of 219.
Quarterly Results
| Metric | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹66 Cr | ₹77 Cr | ₹73 Cr | ₹76 Cr | ₹71 Cr | ₹56 Cr | ₹73 Cr | ₹71 Cr |
| EBITDA | ₹8 Cr | ₹6 Cr | ₹7 Cr | ₹10 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
| Net Profit | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹9 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹21 Cr | ₹11 Cr | ₹295 Cr | ₹10 Cr | ₹17 Cr | ₹19 Cr | ₹25 Cr | ₹20 Cr |
| EBITDA | ₹3 Cr | ₹3 Cr | ₹32 Cr | ₹0 Cr | ₹1 Cr | ₹5 Cr | ₹3 Cr | ₹1 Cr |
| Net Profit | ₹2 Cr | ₹2 Cr | ₹25 Cr | ₹-1 Cr | ₹0 Cr | ₹3 Cr | ₹2 Cr | ₹0 Cr |
| EPS | — | — | 4.54 | — | — | — | — | — |
Balance Sheet
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | ₹6 Cr | ₹36 Cr | ₹100 Cr | ₹176 Cr | ₹240 Cr | ₹258 Cr | ₹310 Cr |
| Total Liabilities | ₹3 Cr | ₹8 Cr | ₹35 Cr | ₹63 Cr | ₹57 Cr | ₹57 Cr | ₹79 Cr |
| Equity | ₹4 Cr | ₹28 Cr | ₹65 Cr | ₹113 Cr | ₹183 Cr | ₹201 Cr | ₹232 Cr |
| Total Debt | — | — | — | — | — | — | — |
Cash Flow
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Operating | ₹-1 Cr | ₹-13 Cr | ₹3 Cr | ₹40 Cr | ₹18 Cr | ₹12 Cr | ₹-32 Cr |
| Investing | ₹0 Cr | ₹0 Cr | ₹-6 Cr | ₹-28 Cr | ₹-11 Cr | ₹-1 Cr | ₹-22 Cr |
| Financing | ₹0 Cr | ₹18 Cr | ₹4 Cr | ₹0 Cr | ₹26 Cr | ₹30 Cr | ₹34 Cr |
| Free Cash Flow | ₹-1 Cr | ₹-13 Cr | ₹3 Cr | ₹40 Cr | ₹16 Cr | ₹12 Cr | ₹-32 Cr |
Shareholding
Promoter 65.99% Institutions 2.56% Public 31.45%
Efficiency & Working Capital
ROCE5.1%
Interest Coverage8.2
Dividend Payout—
Debtor Days138 d
Inventory Days98 d
Payable Days20 d
Cash Conversion Cycle216 d
Working Capital Days236 d
Shareholding Details
As of 2026-06-30
Promoter66%
FII0%
DII2.6%
Institutions2.6%
Public31.4%
Promoter Pledge0%
No. of Shareholders14,682
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Mar 2024 | Apr 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 66.4% | 66.4% | 66.4% | 66% | 66% | 66% | 66% | 66% | 66% | 66% | 66% | 66% |
| FIIs | 17.1% | 17.1% | 17.1% | 16.9% | 16.5% | 16.5% | 16% | 8.9% | 3.5% | 1.7% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 2.6% | 2.6% |
| Public | 16.5% | 16.5% | 16.5% | 17.1% | 17.5% | 17.5% | 18% | 25.1% | 30.5% | 32.2% | 31.4% | 31.4% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 5,132 | 5,132 | 5,132 | 6,586 | 7,863 | 8,529 | 9,994 | 13,737 | 14,620 | 15,085 | 15,176 | 14,682 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202503 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Balaxi Overseas Private Limited | Shareholding of Promoter and Promoter Group | 63.4% | 3.50 Cr |
| Rgsl Investment Fund - Rgsl Investment Lvf 1 | Public Shareholding | 2.5% | 14,00,537 |
| Kunal Mahendra Bhakta | Public Shareholding | 1.9% | 10,28,855 |
| Ashish Maheshwari | Shareholding of Promoter and Promoter Group | 1.6% | 9,03,870 |
| Amol Anand Mantri | Public Shareholding | 1.4% | 7,78,176 |
| P P Zibi Jose | Public Shareholding | 1.3% | 7,10,821 |
| Minoshi Maheshwari | Shareholding of Promoter and Promoter Group | 1% | 5,27,900 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Ashish Maheshwari | Managing Director | 2024 |
| Minoshi Maheshwari | Non Executive Director | 2024 |
| Kunal M Bhakta | Independent Non Exe. Director | 2024 |
| Gandhi Gamji | Independent Non Exe. Director | 2024 |
| M. Srinivas Rao | Independent Non Exe. Director | 2024 |
| Mohith Kumar Khandelwal | Company Sec. & Compli. Officer | 2024 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Specialized Wholesale | ₹0 Cr | — |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2025 | ₹2 | 40 | 11 | 11 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-05 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2025 | 61 | 0 | 0 | 2 | 0 | 63 |
| 2025 | 0 | 0 | 0 | 2 | 0 | 2 |
| 2025 | 61 | 0 | 0 | 0 | 0 | 61 |
Company Information
🌐 www.balaxipharma.in ↗
📍 41/298-D2 2nd Flr Saniya Plaza, Mahakavi Bharatiyar Road, Cochin, Kerala, 682035
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Bajel Projects LimitedBajaj Finance LimitedShree Tirupati Balajee Agro Trading Co. Ltd.Balaji Phosphates LimitedBalaji Telefilms Limited.Balaji Amines LimitedSolve Plastic Products LimitedBalkrishna Paper Mills LimitedBalkrishna Industries Ltd.Balmer Lawrie & Company Ltd.Bal Pharma Ltd.Balrampur Chini Mills Ltd.All “B” stocks →
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search